Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Dyadic International
Dyadic International
Activities:
Ingredients
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer
Denis will be responsible for optimising global operations for the company
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Dyadic C1 gene expression produces RBD at 3 g/L in 5 days
Dyadic says it has expressed a SARS-CoV-2 mAb in collaboration with a biotech company who is developing antibody cocktails to treat COVID-19 patients
Research & Development
Is the production of biologic drugs ready for an overhaul?
Is the industry ready for a new manufacturing model? Mark Emalfarb, President and CEO of Dyadic International, thinks so and explains why to Dr Kevin Robinson
Finance
Dyadic to sell enzyme and technology assets to DuPont for US$75m
Aims to concentrate on its biosimilars business
Ingredients
Dyadic Nederland enters r&d deal with Sanofi Pasteur
Sanofi Pasteur to fund research using Dyadic\'s C1 technology for certain vaccine applications
Subscribe now